ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 720

Impact of HLA-B27 on Patient Profile and Treatment Response in As Patients Treated with Anti-TNF in Canadian Real-World

Isabelle Fortin1, Maqbool Sheriff2, Proton Rahman3, Michael Starr4, Wojciech Olszynski5, Sanjay Dixit6, Viktoria Pavlova7, Derek Haaland8, Emmanouil Rampakakis9, Eliofotisti Psaradellis10, Brendan Osborne11, Karina Maslova12, Allen J Lehman12, Francois Nantel13 and Cathy Tkaczyk11, 1Centre de Rhumatologie De l’Est du Quebec, Rimouski, QC, Canada, 2Nanaimo Regional General Hospital, Nanaimo, BC, Canada, 3Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada, 4Rheumatology, Mcgill University, Pointe-Claire,, QC, Canada, 5103 Midtown Professional Center, Rheumatology Associates of Saskatoon, Saskatoon, SK, Canada, 6Rheumatology, McMaster University Hamilton, Burlington, ON, Canada, 7Ancaster Medical Centre, Ancaster, ON, Canada, 8Rheumatology, Clinical Immunology & Allergy, McMaster University, Barrie, ON, Canada, 9JSS Medical Research, St-Laurent, QC, Canada, 10JSS Medical Research, Montreal, QC, Canada, 11Medical Affairs, Janssen Inc., Toronto, ON, Canada, 12Janssen Inc., Toronto, ON, Canada, 1319 Green belt Dr, Janssen Inc., Toronto, ON, Canada

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Ankylosing spondylitis (AS) and anti-TNF therapy

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Session Title: Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster I: Axial and Peripheral Spondyloarthritis – Clinical Aspects, Imaging and Treatment

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:  The human leukocyte antigen (HLA)-B27 allele is one of the strongest known genetic factors associated with the development of ankylosing spondylitis, however, previous studies have shown that approximately 10-25% of AS patients are HLA-B27 negative (HLA-). The aim of this analysis was to compare the profile of HLA – and HLA+ AS patients initiating anti-TNF treatment in Canadian routine clinical care.

Methods:

BioTRAC is an ongoing, prospective registry of patients initiating treatment with infliximab (IFX) or golimumab (GLM) for RA, AS, or PsA, or with ustekinumab for psoriasis. Patients eligible for this analysis included AS patients treated with IFX or GLM, enrolled since 2005 and 2010, respectively with available information on HLA B27 status. Descriptive statistics were used to assess patient and disease characteristics at Baseline and Month 12. Multivariate general linear models were used to assess the impact of HLA status on BASFI, BASDAI and ASDAS at Month 12 while adjusting for age, gender, disease duration, anti-TNF type, and baseline scores.

Results:

A total of 147 HLA+ and 78 HLA- AS patients were included, of which 93 had available data at Month 12 (62 HLA+, 31 HLA-). Table 1 summarizes the baseline patient characteristics and disease parameters by HLA status. HLA+ patients were significantly younger compared to HLA- patients both at diagnosis (32.2 vs. 46.8 years; P=0.001) and at anti-TNF initiation (42.1 vs. 48.2 years; P=0.002). Furthermore, HLA+ patients had significantly higher disease duration (7.7 vs. 3.9 years; P=0.002) and were more likely to be male (69.0% vs. 42.1%; P<0.001). Geographic distribution was comparable between HLA+ and HLA- groups (P=0.886). With respect to disease parameters, baseline BASDAI, BASFI and ASDAS were significantly higher in the HLA- group (P < 0.05), as was the proportion of HLA- patients reporting very high ASDAS disease activity (62.5% vs. 38.2%). Mean baseline CRP levels, although higher in HLA- patients compared to HLA+ patients (16.7 vs. 10.5 mg/L), were not found to be significantly different between groups (P=0.085).

Upon adjusting for potential confounders, HLA+ patients experienced greater improvements from baseline to Month 12 in BASDAI (-2.13 vs. -0.24; P=0.008), BASFI (-1.64 vs. 0.11; P=0.030), and ASDAS (-0.95 vs. -0.26; P=0.067). At Month 12, ASDAS DA categories were found to be statistically comparable across both groups (P=0.396), although a lower proportion of HLA – patients reported inactive-moderate disease (30.0% vs. 51.2%).

Table 1. Patient and Disease Characteristics at anti-TNF Initiation by HLA Status

 Parameter

HLA+

(N=147)

HLA-

(N=78)

P-value

Age, years, mean (SD)

42.1 (13.2)

48.2 (13.4)

0.002

Age at diagnosis, mean (SD)

32.2 (9.0)

46.8 (14.0)

0.001

Disease duration, years, mean (SD)

7.7 (10.3)

3.9 (4.4)

0.002

Gender, male, n (%)

98 (69.0)

44 (31.0)

< 0.001

Anti-TNF at baseline

Infliximab, n (%)

27 (18.4)

15 (19.2)

0.504

Golimumab, n (%)

120 (81.6)

63 (80.2)

CRP levels, mg/L, mean (SD)

10.5 (20.2)

16.7 (29.2)

0.084

BASDAI, mean (SD)

5.9 (2.2)

6.6 (1.7)

0.022

BASFI, mean (SD)

5.0 (2.6)

5.9 (2.2)

0.026

ASDAS, mean (SD)

3.2 (0.96)

3.7 (0.90)

0.002

ASDAS Disease Activity (DA), %

Inactive DA

2.7

0.0

Moderate DA

5.5

3.6

0.022

High DA

53.6

33.9

Very high DA

38.2

62.5

Conclusion:  In this Canadian real-world cohort, HLA- AS patients were found to be demographically distinct from HLA+ patients and present with more advanced disease at baseline. Furthermore, HLA- was identified as an independent predictor of worse treatment outcomes, highlighting the importance of early diagnosis and management of HLA- AS patients.


Disclosure: I. Fortin, None; M. Sheriff, Janssen Inc., 5; P. Rahman, Janssen Inc., 5; M. Starr, Janssen Inc., 5; W. Olszynski, Janssen Inc., 5; S. Dixit, Janssen Inc., 5; V. Pavlova, Janssen Inc., 5; D. Haaland, None; E. Rampakakis, employee of JSS Medical Research, 3; E. Psaradellis, employee of JSS Medical Research, 3; B. Osborne, Employee of Janssen Inc., 3; K. Maslova, Employee of Janssen Inc., 3; A. J. Lehman, Employee of Janssen Inc., 3; F. Nantel, Employee of Janssen Inc., 3; C. Tkaczyk, Employee of Janssen Inc., 3.

To cite this abstract in AMA style:

Fortin I, Sheriff M, Rahman P, Starr M, Olszynski W, Dixit S, Pavlova V, Haaland D, Rampakakis E, Psaradellis E, Osborne B, Maslova K, Lehman AJ, Nantel F, Tkaczyk C. Impact of HLA-B27 on Patient Profile and Treatment Response in As Patients Treated with Anti-TNF in Canadian Real-World [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/impact-of-hla-b27-on-patient-profile-and-treatment-response-in-as-patients-treated-with-anti-tnf-in-canadian-real-world/. Accessed May 17, 2022.
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-hla-b27-on-patient-profile-and-treatment-response-in-as-patients-treated-with-anti-tnf-in-canadian-real-world/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.